*Coloplast slips on negative broker comments. *Telecom Italia up on report Vivendi to increase stake. Danish medical equipment maker Coloplast was the biggest faller after a string of banks cut their target price for the stock, a day after the company lowered its guidance for 2014/ 15. Its shares fell 2.8 percent, having dropped 7.8 percent in the previous session.» Read More
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
Johnson & Johnson's stock has gained 22 percent on the year and trades at a higher P/E ratio than its competitors. It is not a good buy now, but a great hold, TheStreet.com says.
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.
The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.
Roger Parloff, Fortune senior editor, says businesses are sprouting in states like Colorado and Washington, where selling cannabis is now legal.
If you smoke, you might have to pay thousands extra for employee-based health insurance under Obamacare starting next year.
On a First on CNBC interview, Cochlear CEO Chris Roberts tells CashFlow about his company's products and plans for global expansion.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
Pfizer's unit Zoetis plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering.
One of the worst flu seasons in a decade is putting further strains on an already sluggish U.S. economy as companies get slammed with increased health care costs and lower productivity from widespread worker absences.
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.
The managing partner of Google's venture capital, Bill Maris, says under-investment in health sciences is short-sighted.
The goal is to enable physicians and pharmaceutical companies to use complex genetic data to tailor treatment on an individual basis, according to Mike Pellini, CEO of Foundation Medical.
According to the CDC, the death toll has now reached 8 from a contaminated steroid used to treat back pain that came from a Massachusetts Compounding pharmacy. The next update from the CDC will be at 2PM EST today.
Qualcomm's CEO Paul Jacobs says the smart phone will become a focal point for wirelessly connecting medical devices, diagnostics and sensors, and providing near real-time information.
The aging of America is taking a toll on the health care system. By 2050, the cost of treating Alzheimer's patients will hit $1 trillion a year.
Despite piles of research on the skin cancer risks of sun exposure and tanning beds, dermatologists and cancer groups struggle to persuade people to protect their skin from ultraviolet rays.
With 12 million Americans allergic to one food item or another, sales of specialty foods are soaring.
A warning letter written by the Food & Drug Administration last week to ten companies that produce pre-workout supplements with the ingredient dimethylamyamine (DMAA) has sent shockwaves through the industry, not only to the producers of the products but to consumers who have taken them.